Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Pediatr Diabetes ; 18(4): 315-319, 2017 06.
Article in English | MEDLINE | ID: mdl-27161659

ABSTRACT

BACKGROUND/OBJECTIVE: The impact of family composition on glycemic control in children with type 1 diabetes remains unclear. We sought to evaluate the relationship between health insurance coverage, family composition, and insulin management, and assess their impact on glycemic control in a pediatric type 1 diabetes population. METHODS: A retrospective chart review was completed for patients seen in the Pediatric Endocrinology Clinic at the University of Louisville in 2012. RESULTS: The analysis included 729 patients with type 1 diabetes; 268 (37%) had public insurance while 461(63%) had private insurance. Compared with publicly insured patients, privately insured patients had higher rates of intensive insulin management with multiple daily injections (MDI) plans or pump devices (88 vs. 83.2%, p = 0.066) and lower HbA1c levels [8.57 vs. 9.39% (70 vs. 79 mmol/mol), p < 0.001]. Of the 729 patients, 243 were in single-adult homes (33%). Single-adult homes had higher HbA1c levels than two-adult homes, [9.3 vs. 8.6% (78 vs. 70 mmol/mol), p < 0.001]. Among publicly insured, there was no difference in HbA1c levels for single-adult vs. two-adult homes [9.4 (79 mmol/mol), p = 0.868]. For privately insured, patients in single-adult homes had higher HbA1c levels than peers in two-adult homes [9.2 vs. 8.4% (77 vs. 68), p < 0.001]. CONCLUSION: Insurance type and family composition have significant associative effects on glycemic control and insulin management that may be mitigated by insulin pump therapy. Identifying and addressing factors such as availability of resources, family education, and adult support and supervision, may help improve glycemic control in high-risk pediatric diabetes patients.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Family , Hyperglycemia/prevention & control , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Insurance, Health , Self-Management , Biomarkers/blood , Cohort Studies , Combined Modality Therapy/economics , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/economics , Diabetes Mellitus, Type 1/therapy , Drug Administration Schedule , Female , Glycated Hemoglobin/analysis , Health Expenditures , Hospitals, University , Humans , Hyperglycemia/economics , Hypoglycemic Agents/economics , Hypoglycemic Agents/therapeutic use , Insulin/economics , Insulin/therapeutic use , Insulin Infusion Systems/economics , Kentucky , Male , Outpatient Clinics, Hospital , Retrospective Studies , Self-Management/economics , Single Parent
4.
J Pediatr Endocrinol Metab ; 28(5-6): 721-4, 2015 May.
Article in English | MEDLINE | ID: mdl-25581742

ABSTRACT

We report a 9-year-old female who presented with new onset intractable seizure activity followed by a prolonged encephalopathic state. After ruling out common etiologies, Hashimoto's encephalopathy (HE) was considered, and antibody levels to thyroid peroxidase and thyroglobulin were both markedly elevated in her serum. She was euthyroid at the time of presentation. Upon treatment with high dose methylprednisolone, the patient demonstrated a significant improvement in her encephalopathy. The diagnosis of HE requires strong clinical suspicion with evidence of antithyroid antibodies, as well as an encephalopathy not explained by another etiology. While well documented in the adult literature, only a handful of pediatric cases have been described to date. Patients with HE have a nearly universal response to high dose glucocorticoids. HE should be considered in the differential diagnosis of any patient, adult or pediatric, who displays prolonged, unexplainable encephalopathy.


Subject(s)
Encephalitis/diagnosis , Hashimoto Disease/diagnosis , Child , Encephalitis/complications , Encephalitis/drug therapy , Female , Hashimoto Disease/complications , Hashimoto Disease/drug therapy , Humans , Magnetic Resonance Imaging , Methylprednisolone/therapeutic use , Seizures/complications
5.
Laryngoscope ; 123(2): 524-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22570138

ABSTRACT

We present a case of a left-sided neck mass in an 8-year-old female that proved to be ectopic thyroid tissue. After excision, this patient continues to do well and is euthyroid without recurrence after 8-year follow-up. This is a very rare anomaly in a child, especially in conjunction with a normally located thyroid that is functional. We reviewed the literature of displaced ectopic thyroid tissue.


Subject(s)
Choristoma/diagnosis , Lymphatic Diseases/diagnosis , Thyroid Gland , Child , Choristoma/surgery , Diagnosis, Differential , Female , Humans , Laryngoscopy , Lymphatic Diseases/surgery , Neck , Positron-Emission Tomography , Tomography, X-Ray Computed
6.
J Diabetes Sci Technol ; 6(1): 5-14, 2012 Jan 01.
Article in English | MEDLINE | ID: mdl-22401317

ABSTRACT

BACKGROUND: Studies of pediatric intensive care unit (PICU) patients have shown a significant association of morbidity and mortality with hyperglycemia. We retrospectively evaluated the degree of hyperglycemia as well as its correlation with glucocorticoid and insulin use and assessed its association with hospital length of stay (LOS) and mortality. This study preceded the initiation of a standard glycemic control protocol. METHODS: We examined medical records at Kosair Children's Hospital for all PICU admissions from 2008 of patients without diabetes mellitus. Critical illness hyperglycemia (CIH) was defined by having three or more peak glucose values greater than thresholds of 110, 140, 180, and 200 mg/dl. These patients were evaluated for glucocorticoid, insulin use, and outcome measures. RESULTS: We evaluated the eligible 1173 admissions, where 10.5% of these patients reached the highest threshold (200 mg/dl) of CIH. Glucocorticoids were used in 43% of these patients, with dexamethasone being the most common (58%). There was a significant correlation between glucocorticoids and higher peak glucose values, where 81% of the patients who were above the 200 mg/dl cutoff level were treated with glucocorticoids. Only 36.8% in that group were also treated with insulin. Patients at the 200 mg/dl cutoff had the highest median PICU and total hospital length of stays (4 and 10 days, respectfully). Mortality was associated with increasing glucose levels, reaching 18.7% among patients above the 200 mg/dl cutoff. CONCLUSION: Hyperglycemia was prevalent in the PICU and was associated with increased morbidity, as characterized by increased LOS and increased mortality. Glucocorticoid use was prevalent among patients exhibiting hyperglycemia. Insulin use was uncommon.


Subject(s)
Critical Illness/mortality , Diabetes Mellitus/epidemiology , Glucocorticoids/therapeutic use , Hyperglycemia/epidemiology , Insulin/therapeutic use , Intensive Care Units, Pediatric/statistics & numerical data , Adolescent , Blood Glucose/analysis , Blood Glucose/physiology , Child , Child, Preschool , Critical Illness/epidemiology , Critical Illness/therapy , Diabetes Mellitus/drug therapy , Diabetes Mellitus/mortality , Female , Glucocorticoids/adverse effects , Hospital Mortality , Humans , Hyperglycemia/complications , Hyperglycemia/mortality , Infant , Infant, Newborn , Insulin/adverse effects , Length of Stay , Male , Morbidity , Mortality , Retrospective Studies , Young Adult
7.
J Pediatr Endocrinol Metab ; 24(5-6): 385-7, 2011.
Article in English | MEDLINE | ID: mdl-21823542

ABSTRACT

A 15-year-old female presented to a pediatric emergency department with glycosuria, ketonuria, and hyperglycemia and was admitted with a presumed diagnosis of diabetes mellitus. The patient required no insulin therapy and only minor dietary modification to maintain euglycemia. Clinical examination and laboratory findings revealed a primary diagnosis of Graves' hyperthyroidism with associated impaired glucose tolerance. Here, we review the mechanisms of thyrotoxicosis resulting in impaired glucose metabolism.


Subject(s)
Graves Disease/complications , Hyperglycemia/etiology , Adolescent , Adrenergic beta-Antagonists/therapeutic use , Antithyroid Agents/therapeutic use , Blood Glucose/metabolism , Female , Graves Disease/blood , Graves Disease/diagnosis , Graves Disease/therapy , Humans , Hyperglycemia/blood , Iodine Radioisotopes/therapeutic use , Methimazole/therapeutic use , Propranolol/therapeutic use , Thyrotoxicosis/blood , Thyrotoxicosis/complications , Thyrotoxicosis/diagnosis , Thyrotoxicosis/therapy , Thyroxine/therapeutic use
8.
Diabetes Res Clin Pract ; 90(1): 40-4, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20630611

ABSTRACT

AIMS: To examine the association between health insurance coverage, insulin management plans, and their impact on diabetes control in a pediatric type 1 diabetes mellitus clinic population. METHODS: Retrospective cohort design drawn from the medical records of the Pediatric Endocrinology Clinic at the University of Louisville, Kentucky. RESULTS: Out of 701 patients, 223 had public insurance, and 478 had private insurance. 77% of publically insured used two or three injections per day vs. 40% private. Conversely, 58% of privately insured used a multiple daily injection (MDI) plan or insulin pump (vs. 21%). 84% of MDI patients had private insurance with 93% using insulin pens compared with 38% of publically insured. Mean HbA1c was 8.6% for privately insured vs. 9.8% public, p<0.0001. Privately insured MDI and pump patients had the lowest HbA1cs. CONCLUSIONS: Insurance type had a significant effect on the insulin management plan used and was the most significant factor in overall diabetes control. Limitations on insulin pen use and number of glucose test strips may play a role in the decreased use of MDI/insulin pumps by publicly insured patients. Addressing factors related to insurance type, including availability of resources, could substantially improve diabetes control in those with public insurance.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/economics , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Insurance Coverage/statistics & numerical data , Insurance, Health , Adolescent , Blood Glucose Self-Monitoring/economics , Child , Child, Preschool , Cohort Studies , Diabetes Mellitus, Type 1/blood , Female , Glycated Hemoglobin/analysis , Hospitals, University , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/economics , Insulin/administration & dosage , Insulin/economics , Insulin Infusion Systems/statistics & numerical data , Male , Medical Records , National Health Insurance, United States , Outpatient Clinics, Hospital/statistics & numerical data , Retrospective Studies , United States , Young Adult
9.
J Pediatr ; 156(2): 221-5, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19892364

ABSTRACT

OBJECTIVE: To determine whether phthalate exposure is associated with precocious puberty in girls. STUDY DESIGN: This was a multicenter cross-sectional study in which 28 girls with central precocious puberty (CPP) and 28 age- and race-matched prepubertal females were enrolled. Nine phthalate metabolites and creatinine were measured in spot urine samples from these 56 children. RESULTS: Levels of 8 of the 9 phthalate metabolites were above the limit of detection (LOD) in all 56 subjects. Mono (2-ethylhexyl) phthalate (MEHP) was below the LOD in 25/56 samples (14 subjects with precocious puberty and 11 controls). No significant differences between the children with CPP and the controls in either absolute or creatinine-normalized concentrations of any of the 9 phthalate metabolites were measured. CONCLUSIONS: Although phthalates may be associated with certain other toxicities in humans, our study suggests that their exposure is not associated with precocious puberty in female children.


Subject(s)
Environmental Exposure/adverse effects , Phthalic Acids/adverse effects , Puberty, Precocious/etiology , Black or African American/statistics & numerical data , Case-Control Studies , Child , Cross-Sectional Studies , Environmental Exposure/analysis , Female , Humans , Lod Score , Matched-Pair Analysis , Phthalic Acids/urine , Puberty, Precocious/epidemiology , United States/epidemiology , White People/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...